Skip to main content

Volumetric Tumor Segmentation for Disease Progression Analysis in Metastatic Melanoma

Thursday, October 11, 2012 — Poster Session III

10:00 a.m. – Noon

Natcher Conference Center, Building 45




  • M Choi
  • MS Hughes
  • L Folio
  • N Schaub
  • SA Rosenberg
  • AM Venkatesan


Background Conventional imaging evaluation of tumor burden in metastatic disease is limited to axial measurements of target lesions, which serve as a surrogate assessment for three dimensional changes in tumor size. Rigorous assessment of tumor response to cancer therapy is dependent upon assessment of these three dimensional changes. A major barrier to moving from anatomic uni-dimensional assessment of tumor burden to volumetric anatomical assessment is the insufficient evidence that exists to abandon anatomic uni-dimensional assessment. Newer image-processing algorithms enabling efficient volumetric tumor assessment should facilitate the clinical validation studies necessary for mainstream use of volumetric tumor assessment. Purpose Compare RECIST and semi-automated volume (SAV) tumor measurements using an experimental image-processing algorithm within PACS in a retrospective cohort of patients with metastatic melanoma treated with adoptive cell therapy. Hypothesis Semi-automated volume tumor measurements more accurately reflect tumor burden and treatment response over axial measurements alone. Specific Aims 1. Retrospectively assess RECIST and SAV target lesion measurements 2. Correlate SAV, RECIST and clinical treatment response on all metastatic lesions Clinical impact This is the first known study employing semi-automated volume measurement to assess disease progression in metastatic melanoma to all metastatic sites. SAV measurements may improve the accuracy of oncologic staging.

back to top